Research Analysts Issue Forecasts for MBOT Q2 Earnings

Microbot Medical Inc. (NASDAQ:MBOT - Free Report) - Stock analysts at HC Wainwright lifted their Q2 2025 earnings per share estimates for shares of Microbot Medical in a research report issued on Tuesday, June 10th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will post earnings per share of ($0.08) for the quarter, up from their prior forecast of ($0.12). HC Wainwright currently has a "Buy" rating and a $9.00 price objective on the stock. The consensus estimate for Microbot Medical's current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Microbot Medical's Q3 2025 earnings at ($0.08) EPS and FY2025 earnings at ($0.32) EPS.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last posted its earnings results on Wednesday, May 21st. The biotechnology company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.07.

Separately, Wall Street Zen raised Microbot Medical from a "sell" rating to a "hold" rating in a research report on Saturday.

Microbot Medical Price Performance

Shares of NASDAQ:MBOT traded down $0.14 during midday trading on Thursday, reaching $2.34. 1,334,092 shares of the company's stock were exchanged, compared to its average volume of 1,738,818. The firm's 50 day simple moving average is $2.46 and its two-hundred day simple moving average is $1.87. The stock has a market cap of $85.12 million, a price-to-earnings ratio of -2.92 and a beta of 1.14. Microbot Medical has a fifty-two week low of $0.82 and a fifty-two week high of $3.38.

Hedge Funds Weigh In On Microbot Medical

Several institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC purchased a new position in shares of Microbot Medical in the 4th quarter valued at about $118,000. Goldman Sachs Group Inc. purchased a new stake in Microbot Medical in the first quarter valued at approximately $57,000. Virtu Financial LLC acquired a new position in shares of Microbot Medical in the first quarter valued at approximately $42,000. Finally, Geode Capital Management LLC increased its holdings in shares of Microbot Medical by 7.9% in the fourth quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company's stock valued at $160,000 after purchasing an additional 10,442 shares during the period. 16.30% of the stock is owned by institutional investors and hedge funds.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.